Using ELISA technique, we detected a significant decrease in HIF-1α levels in the blood serum of mice receiving SXT treatment (Figure 5) suggesting, at least in part, that SXT may exert anti-tumor activity by modulating HIF-1α-related signaling pathways. The gene discussed is HIF1A; the disease is neoplasm.